In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The fourth-quarter earnings season picks up speed in the coming week, unperturbed by new leadership in Washington that could roil the markets.
Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.
Biogen will pay Forward $1.25 billion.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.